Abstract
SINCE its discovery1, endothelin-1 has attracted considerable scientific interest because of its extremely potent and long-lasting vasoconstrictor effect and its binding to G-protein-coupled receptors2. Plasma concentrations of endothelin-1 are low3 and its release by endothelial cells is polarized towards the basolateral side4,5, suggesting that it is a paracrine factor and not a hormone. Consequently, the effect of injected endothelin-1 may not reflect the effect of endogenous endothelin-1. In contrast, blockade of the action of endogenous endothelin-1 using receptor antagonists should be a valuable means of investigating its physiological and pathological effects. We report here evidence for the pathophysiological role of endothelin-1 as brought by the first synthetic orally active non-peptide antagonist of endothelin receptors, Ro 46-2005.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Yanagisawa, M. et al. Nature 332, 411–415 (1988).
Kasuya, Y., Takuwa, Y., Yanagisawa, M., Masaki, T. & Goto, K. Br. J. Pharmac. 107, 456–462 (1992).
Ando, K., Hirata, Y., Shichiri, M., Emori, T. & Marumo, F. FEBS Lett. 245, 164–166 (1989).
Wagner, F. et al. J. biol. Chem. 267, 16066–16068 (1992).
Yoshimoto, S. et al. J. cardiovasc. Pharmac. 17(suppl.7), S260–S263 (1991).
Arai, H., Hori, S., Aramori, I., Ohkubo, H. & Nakanishi, S. Nature 348, 730–732 (1990).
Sakurai, T. et al. Nature 348, 732–735 (1990).
Emori, T., Hirata, Y. & Marumo, F. FEBS Lett. 263, 261–264 (1990).
Sokolovsky, M., Ambar, I. & Galron, R. J. biol. Chem. 267, 20551–20554 (1992).
Ihara, M. et al. Life Sci. 50, 247–255 (1993).
Takayanagi, R. et al. FEBS Lett. 282, 103–106 (1991).
Clozel, M., Gray, G. A. & Breu, V. Biochem. biophys. Res. Commun. 186, 867–873 (1992).
Moreland, S., McMullen, D. M. Delaney, C. L., Lee, V. G. & Hunt, J. T. Biochem. biophys. Res. Commun. 184, 100–106 (1992).
McMurdo, L., Corder, R., Thiemermann, C. & Vane, J. R. Br. J. Pharmac. 108, 557–561 (1993).
Harrison, V. J., Randriantsoa, A. & Schoeffter, Ph. Br. J. Pharmac. 105, 511–513 (1992).
Lerman, A. et al. New Engl. J. Med. 325, 997–1001 (1991).
McMurray, J. J. et al. Circulation 85, 1374–1379 (1992).
Dohi, Y. & Lüscher, T. F. Hypertension 18, 543–549 (1991).
Fischli, W., Clozel, M. & Guilly, C. Life Sci. 44, 1429–1436 (1989).
Arunlakshana, O. & Schild, H. O. Br. J. Pharmac. Chemother. 14, 48–58 (1959).
Williams, D. L. Jr, Jones, K. L., Pettibone, D. J., Lis, E. V. & Clineschmidt, B. V. Biochem. biophys. Res. Commun. 175, 556–561 (1991).
Clozel, M., Löffler, B.-M. & Gloor, H. J. cardiovasc. Pharmac. 17(suppl. 7), S313–S315 (1991).
Mino, N. et al. Eur. J. Pharmac. 221, 77–83 (1992).
Webb, M. L. et al. Biochem. biophys. Res. Commun. 185, 887–892 (1992).
Clozel, M. & Watanabe, H. Life Sci. 52, 825–834 (1993).
Solomon, R. A. et al. Stroke 16, 58–64 (1985).
Suzuki, R. et al. J. Neurosurg. 77, 96–100 (1992).
Clozel, M. J. Hypertension 7, 913–917 (1989).
Mulvany, M. J. & Halpern, W. Circ. Res. 41, 19–26 (1977).
Heymann, M. A. & Payne, B. D., Hoffman, J. I. E. & Rudolph, A. M. Progr. cardiovasc. Dis. 20, 55–79 (1977).
Clozel, J. P., Fischli, W. & Ménard, J. J. Hypertension 11, 75–81 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Clozel, M., Breu, V., Burri, K. et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 365, 759–761 (1993). https://doi.org/10.1038/365759a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/365759a0
This article is cited by
-
Fly casting with ligand sliding and orientational selection supporting complex formation of a GPCR and a middle sized flexible molecule
Scientific Reports (2022)
-
Crystal structure of human endothelin ETB receptor in complex with peptide inverse agonist IRL2500
Communications Biology (2019)
-
Combinatorial therapy with two pro-coagulants and one osmotic agent reduces the extent of the lesion in the acute phase of spinal cord injury in the rat
Intensive Care Medicine Experimental (2017)
-
X-ray structures of endothelin ETB receptor bound to clinical antagonist bosentan and its analog
Nature Structural & Molecular Biology (2017)
-
Activation mechanism of endothelin ETB receptor by endothelin-1
Nature (2016)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.